Database

Startups

Main Industry
Health Care
Main Product/Service
Xgene’s key products are clinical-stage analgesic candidates, including oral dual‑mechanism conjugates and topical gels, designed to enhance efficacy and safety through multimodal mechanisms and high target specificity.
Founded Year
2015
Unified Business No.
42836798
Status
Active
Number of Employees
0
Total Paid-in Capital
100,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Xgene Pharmaceutical Inc. is an innovative biotech company focused on neurological disorders and pain management, using proprietary linker technology to develop dual‑acting prodrugs aimed at safer and more effective next‑generation analgesic therapies.



More ↓

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

AnHorn Medicines Co., Ltd.

AnHorn’s flagship therapeutic modality is BIGPRO®, a bi‑functional ligand that induces targeted degradation of disease-causing proteins. Using their proprietary AIMCADD® platform (which integrates AI, bioinformatics, and medicinal chemistry), AnHorn rapid

GenomeFrontier Therapeutics TW Co., Ltd.

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and